Matthew Gall, Chief Financial Officer at iTeos Therapeutics, Inc. (ITOS), bought 5,000 shares at $7.73 ($39K) on 2024-11-19, disclosed to the SEC on 2024-11-19.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Clearly above the average filing.
| Filing → |
| ITOS | BUY | 2021-06-16 | $130K | — | Filing → |